Baxter International Inc.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:02 29/06/2024 am IST			5-day change	1st Jan Change
33.45 ^USD	-0.21%		-2.45%	-13.48%

20/06	Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors	CI
12/06	Transcript : Baxter International Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM

Baxter International Inc. : Baxter to Present at 31st Annual J.P. Morgan Healthcare Conference

January 04, 2013 at 07:50 pm IST

MarketScreener.com By

Baxter International Inc. (NYSE: BAX) announced that it will present at the 31^st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 3:00 p.m. (PT).

The live webcast of Baxter's presentation along with the slides can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through February 9, 2013.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Baxter International Inc.
Media Contact
Deborah Spak, (224) 948-2349
or
Investor Contacts
Mary Kay Ladone, (224) 948-3371
Clare Trachtman, (224) 948-3085

Latest news about Baxter International Inc.

Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors	20/06	CI
Transcript : Baxter International Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM	12/06
Transcript : Baxter International Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 09:30 AM	05/06
Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy	29/05	CI
Citigroup Adjusts Price Target on Baxter International to $38 From $44, Keeps Neutral Rating	22/05	MT
Transcript : Baxter International Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	16/05
Baxter International's Clinolipid Injection Approved for Expanded Use in US	13/05	MT
Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication	13/05	CI
TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40	10/05	MT
Declaration of Voting Results by Baxter International Inc	10/05	CI
Baxter International Keeps Quarterly Cash Dividend at $0.29 a Share, Payable July 1 to Shareholders as of May 31	07/05	MT
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024	07/05	CI
UBS Adjusts Price Target on Baxter International to $40 From $42, Maintains Neutral Rating	03/05	MT
Evercore ISI Adjusts Price Target on Baxter International to $46 From $50	03/05	MT
Jefferies Adjusts Price Target on Baxter International to $43 From $45	03/05	MT
Stifel Adjusts Baxter International's Price Target to $44 From $50	02/05	MT
Baxter International Q1 Adjusted Earnings, Net Sales Gain; Boosts 2024 Adjusted Profit Guidance	02/05	MT
Transcript : Baxter International Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
(BAX) BAXTER INTERNATIONAL Forecasts Q2 Adjusted EPS Range $0.65 - $0.67	02/05	MT
(BAX) BAXTER INTERNATIONAL Sees Fiscal Year 2024 Adjusted EPS Range $2.88 - $2.98	02/05	MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Adjusted EPS $0.65 vs. $0.61 Estimate	02/05	MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Revenue $3.59B	02/05	MT
Earnings Flash (BAX) BAXTER INTERNATIONAL Reports Q1 Revenue $3.59B	02/05	MT
Tranche Update on Baxter International Inc.'s Equity Buyback Plan announced on July 25, 2012.	02/05	CI
Baxter International Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI

Chart Baxter International Inc.

Duration

Period

More charts

Company Profile

Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

25/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Baxter International Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

33.45 USD

Average target price

45.44 USD

Spread / Average Target

+35.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BAXTER INTERNATIONAL INC.	-13.48%	1.7TCr
ABBOTT LABORATORIES	-5.60%	18TCr
MEDTRONIC PLC	-4.45%	10TCr
BECTON, DICKINSON AND COMPANY	-4.15%	6.75TCr
DEXCOM, INC.	-8.63%	4.51TCr
CENCORA, INC.	+9.70%	4.44TCr
HOYA CORPORATION	+6.13%	4.07TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	2.98TCr
TERUMO CORPORATION	+14.80%	2.45TCr
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	2.4TCr

Other Medical Equipment, Supplies & Distribution